Université de Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Nantes, France.
OSE Immunotherapeutics, Nantes, France.
Front Immunol. 2020 Feb 18;11:251. doi: 10.3389/fimmu.2020.00251. eCollection 2020.
C-type lectin-like receptors (CLRs) represent a family of transmembrane pattern recognition receptors, expressed primarily by myeloid cells. They recognize not only pathogen moieties for host defense, but also modified self-antigens such as damage-associated molecular patterns released from dead cells. Upon ligation, CLR signaling leads to the production of inflammatory mediators to shape amplitude, duration and outcome of the immune response. Thus, following excessive injury, dysregulation of these receptors leads to the development of inflammatory diseases. Herein, we will focus on four CLRs of the "Dectin family," shown to decode the immunogenicity of cell death. CLEC9A on dendritic cells links F-actin exposed by dying cells to favor cross-presentation of dead-cell associated antigens to CD8 T cells. Nevertheless, CLEC9A exerts also feedback mechanisms to temper neutrophil recruitment and prevent additional tissue damage. MINCLE expressed by macrophages binds nuclear SAP130 released by necrotic cells to potentiate pro-inflammatory responses. However, the consequent inflammation can exacerbate pathogenesis of inflammatory diseases. Moreover, in a tumor microenvironment, MINCLE induces macrophage-induced immune suppression and cancer progression. Similarly, triggering of LOX-1 by oxidized LDL, amplifies pro-inflammatory response but promotes tumor immune escape and metastasis. Finally, CLEC12A that recognizes monosodium urate crystals formed during cell death, inhibits activating signals to prevent detrimental inflammation. Interestingly, CLEC12A also sustains type-I IFN response to finely tune immune responses in case of viral-induced collateral damage. Therefore, CLRs acting in concert as sensors of injury, could be used in a targeted way to treat numerous diseases such as allergies, obesity, tumors, and autoimmunity.
C 型凝集素样受体 (CLRs) 是一类跨膜模式识别受体,主要表达于髓系细胞。它们不仅识别宿主防御的病原体部分,还识别来自死亡细胞的损伤相关分子模式等修饰的自身抗原。CLR 信号交联后会产生炎症介质,从而调节免疫反应的幅度、持续时间和结果。因此,在过度损伤后,这些受体的失调会导致炎症性疾病的发生。在此,我们将重点关注四种被证明可解码细胞死亡免疫原性的“Dectin 家族” CLR。树突状细胞上的 CLEC9A 可将死亡细胞暴露的 F-肌动蛋白连接起来,有利于将与死亡细胞相关的抗原交叉呈递给 CD8 T 细胞。然而,CLEC9A 也会发挥反馈机制来抑制中性粒细胞的募集,防止进一步的组织损伤。巨噬细胞上表达的 MINCLE 可结合坏死细胞释放的核 SAP130 来增强促炎反应。然而,随之而来的炎症会加剧炎症性疾病的发病机制。此外,在肿瘤微环境中,MINCLE 诱导巨噬细胞诱导的免疫抑制和癌症进展。同样,氧化型 LDL 激活 LOX-1 可放大促炎反应,但促进肿瘤免疫逃逸和转移。最后,CLEC12A 识别细胞死亡过程中形成的单钠尿酸盐晶体,抑制激活信号以防止有害炎症。有趣的是,CLEC12A 还能维持 I 型 IFN 反应,以在病毒诱导的附带损伤时精细调节免疫反应。因此,作为损伤传感器的 CLRs 可以被靶向用于治疗许多疾病,如过敏、肥胖、肿瘤和自身免疫。